This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three and six months ended
December 31, 2012 after the NASDAQ Market closes on
Thursday, February 14, 2013. The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from
June 30 to December 31, effective
December 31, 2012. As a result, the six months ended
December 31, 2012 represent a transition period, with the next fiscal year covering the period from
January 1, 2013 through
December 31, 2013.
Conference call and webcast details:
February 14, 2013Time:
4:30 PM ETListen via Internet:
http://ir.pharmacyclics.com/events.cfmToll-free: (877)-407-0778International: (201)-689-8565
Replay Number (Toll Free): (877)-660-6853Replay Number (International): (201)-612-7415Conference ID #: 409002
A webcast replay will be available on the Pharmacyclics website for 30 days.
About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.